Table 3.
Characteristics of Bexsero and Trumenba antigens in PubMLST Neisseria database
| Antigen | Number of isolates | Dominant clonal complex(es) n (%) | Dominant serogroup(s) n (%) | Minimum lifespan (years) | Observed time period | Continents found |
|---|---|---|---|---|---|---|
| fHbp subvariant 3.45 (A05)a | 38 | ST-213: 36 (94.7) | Unassigned: 36 (94.7) | 13 | 1999–2012 | Europe |
| fHbp subvariant 1.55 (B01)a | 0 | NA | NA | NA | NA | NA |
| fHbp variant family 1/subfamily B | 873 | ST-11: 349 (40.0), ST-41/44: 98 (11.2), Unassigned: 92 (7.4) |
W: 241 (27.6), B: 159 (18.2), C: 113 (12.9), A: 76 (8.7) |
77 | 1937–2014 | Africa, Asia, Europe, North America, Oceania, South America |
| fHbp subvariant 1.1 | 73 | ST-32: 66 (90.4) | B: 47 (64.4) | 40 | 1969–2009 | Africa, Asia, Europe, North America, Oceania, South America |
| NadA-3.8 subvariant | 41 | ST-174: 17 (41.5), ST-5: 16 (39.0) |
Y: 16 (39.0), A: 16 (39.0), B: 5 (12.2) |
49 | 1963–2012 | Africa, Asia, Europe, North America, South America |
| NadA-1,2,3 variants | 709 | ST-11: 568 (80.1) | W: 368 (51.9), C: 135 (19.0) |
51 | 1963–2014 | Africa, Asia, Europe, North America, Oceania, South America |
| NHBA variant 2 | 121 | ST-41/44: 98 (80.9) | B: 66 (54.6), C: 12 (9.9), NG: 11 (9.1) |
37 | 1976–2013 | Europe, North America, Oceania, South America |
NA: not available; NG: non-groupable.
a
A05, B01: Pfizer nomenclature.